TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug. 15515013 2005
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE We have previously shown that progesterone inhibits basal and Tumor Necrosis Factor (TNF) α-induced apoptosis in an explant model of human fetal membranes. 29463188 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The concentrations of TNF-α (Tumor Necrosis Factor-α), IL-1β (Interleukin-1β), IL-6 (Interleukin-6) and PGE-2 (Prostaglandin E2) were evaluated using ELISA. 29501766 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE In particular, genes involved in tumour necrosis factor (TNF) signalling were significantly deregulated in MS cases compared with controls. 31810488 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Contribution of the TNF-α (Tumor Necrosis Factor-α)-TNF-Rp55 (Tumor Necrosis Factor Receptor p55) Axis in the Resolution of Venous Thrombus. 30354252 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE In tumour necrosis factor (TNF) signalling, linear (also known as M1) ubiquitin enables full gene activation and prevents cell death. 30420664 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE CD40, CD80, CD86 and major histocompatibility complex (MHC) class II], as well as the production of cytokines [e.g. interleukin (IL)-1β, IL-12p70 and tumour necrosis gactor (TNF)-α] compared with those of unstimulated controls. 21910723 2011
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Of the genes deregulated in SMZLs, special mention may be made of the genes involved in B-cell receptor (BCR) signaling, tumor necrosis factor (TNF) signaling and nuclear factor-kappaB (NF-kappaB) activation, such as SYK, BTK, BIRC3, TRAF3, and LTB. 15914563 2005
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Point mutations in different regions of the tumour necrosis factor-alpha (TNF-alpha) molecule influence anti-tumour cytotoxic/cytostatic activities as well as haemorrhagic tumour necrosis, tumour regression and lethal toxicity in mice. 1526652 1992
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Lipid metabolism, cell differentiation and proliferation, peroxisome proliferator-activated receptor (PPAR), wingless-type MMTV integration site (Wnt), tumor necrosis factor (TNF) signaling, and steroid biosynthesis were significant at days 2, 4, and 8 compared to day 0 (adjusted <i>p</i> < 0.05). 31331100 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE In this study, we investigated the effects of tumor necrosis factor (TNF) signaling on spatiotemporal enhancer-promoter interactions in the human tumor necrosis factor (TNF)/lymphotoxin (LT) gene locus, mediated by CCCTC-binding factor (CTCF)-dependent chromatin insulators. 22354988 2012
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE KEGG pathway analysis revealed a significant enrichment of genes associated with the tumor necrosis factor (TNF) signaling pathway. 31653960 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Individuals with periodontitis have increased systemic levels of acute phase proteins, plasma antibody levels, coagulation factor, total white blood cell count, neutrophils, C reactive protein (CRP), and cytokines such as INF- gamma (Interferon gamma), TNF-α (Tumor necrosis Factor- Alpha), IL (Interleukin)-1β, IL-2 and IL-6. 30384973 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Tumor necrosis factor-α (TNF-α)-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), a member of the tumor necrosis TNFAIP8 family, was found to be involved in the development and progression of several tumors. 28081733 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE It was further observed that pro-inflammatory cytokine like, TNF-α (Tumor Necrosis Factor-α) can antagonize TGF-β2-induced response by down-regulating autophagy, increasing ROS levels and thus inhibiting EMT in HCC cells. 29464083 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE In mouse monocytes, the lipopolysaccharide- (LPS-) induced tumor necrosis-<i>α</i> (TNF-<i>α</i>) synthesis was significantly inhibited by HNK and the MCP : HNK combination in a dose-dependent manner and synergistic effects were clearly demonstrated with the combination on TNF-<i>α</i> inhibition. 28900464 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Autocrine tumor necrosis factor (TNF) signaling in the absence of TAK1 induced spontaneous RIPK1-dependent NLRP3 inflammasome activation and cell death. 29500178 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Tumour necrosis factor (TNF) signalling molecules are considered as promising therapeutic targets of antirheumatic therapy. 15642137 2005
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Therefore, the overall magnitude of tumor cell killing results from the combination of oncolysis, transgene-mediated direct effect such as TNFa-mediated apoptosis, and, perhaps most significantly, from activation of the host immune system against the tumor. 25557131 2015
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE To this end, we identified TNBC-driven molecular pathways such as the Janus kinase-signal transducers, and activators of transcription (JAK-STAT) and tumor necrosis factor (TNF) signaling pathways. 25611337 2015
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Upregulated DEGs were involved in Cell adhesion molecules (ICAM1, intercellular adhesion molecule 1) and tumor necrosis factor (TNF) signaling pathway (FOS, FBJ osteosarcoma oncogene; ICAM1), while downregulated DEGs participated in PPAR signaling pathway (PPARG, peroxisome proliferator-activated receptor gamma). 31149396 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE GO and KEGG analyses revealed roles for the potential mRNA targets of MIR137HG in epithelial cell differentiation and the peroxisome proliferator-activated receptor (PPAR) and tumor necrosis factor (TNF) signaling pathways. 31308745 2019
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE IL-1β (Interleukin-1β) and TNF-α (Tumor Necrosis Factor-α) Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization. 29217508 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The concentrations of TNF-α (Tumor Necrosis Factor-α), IL-1β (Interleukin-1β), IL-6 and PGE-2 (Prostaglandin-E2) were evaluated using ELISA. 30014878 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing. 28373759 2017